Catalog No.: PC-23372Not For Human Use, Lab Use Only.
ACHM-025 is a third generation AKR1C3-activated prodrug, selectively activates by AKR1C3 in the presence of NADPH to form the nitrogen mustard DNA alkylating agent.
ACHM-025 is a third generation AKR1C3-activated prodrug, selectively activates by AKR1C3 in the presence of NADPH to form the nitrogen mustard DNA alkylating agent.
ACHM-025 showsa strong and significant correlation with basal AKR1C3 protein expression, shows selectivity for activation by the AKR1C3 isoform, compared to AKR1C1, AKR1C2 and AKR1C4 in HCT116 cells.
ACHM-025 has potent in vivo efficacy against T-ALL patient-derived xenografts (PDXs) and eradicated the disease in 7 PDXs.
ACHM-025 was significantly more effective than cyclophosphamide both as a single agent and when used in combination with cytarabine/6-mercaptopurine.
ACHM-025 ex vivo cytotoxicity shows a significant inverse correlation with AKR1C3 mRNA expression.
